Poznan, Poland

Medyczne Centrum Hetmanska

Rheumatoid Arthritis

Diffuse Scleroderma

Arthritis

Osteoarthritis

Systemic Scleroderma

Sclerosis

Systemic Lupus Erythematosus

Tanezumab

ART621

Methotrexate

MT-7117

Obinutuzumab

Arana Therapeutics

Mitsubishi Tanabe Pharma

Pfizer

Roche

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Medyczne Centrum Hetmanska | Poznan, Poland

Site insights

Work at this site?

Active trials

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus (ALLEGORY)

Trial sponsors